The National Agency for Food and Drugs Administration and Control (NAFDAC) is informing the public of a circulation of counterfeit Dostinex (Cabergolin) 0.5mg tablet in Nigeria.
The Agency is issuing this alert following the notification received from Pfizer Specialties Limited (The manufacturer of the original product) disclosing a patient’s complaint about the product.
Pfizer has concluded that the product is counterfeit, as the features of Dostinex 0.5mg displayed in the pictures does not meet the Pfizer Dostinex specifications.
1. The shape of the tablets is not corresponding to the authentic Dostinex tablets.
2. The expiry date captured within the Data-Matrix, 24/08/2012, does not match the expiry date printed on the box, 08/2024.
Dostinex contains the active ingredient cabergoline. Cabergoline is used to treat different types of medical problems that occur when too much of the hormone prolactin is produced. It can be used to treat certain menstrual problems, fertility problems in men and women, and pituitary prolactinomas (tumors of the pituitary gland). Dostinex can also be used to prevent the lactation in women after birth.
Risk Statement:
The illegal distribution of substandard medicines or counterfeits poses a risk to health, as the safety, quality and efficacy cannot be guaranteed.
Source: NAFDAC alerts
Leave a Reply